Plasma cell isolation
Unleash the power of innovation
AUTOMATED PRECISION
automatic 2x or 3x separation guarantees unmatched consistency and a seamless user experience
UNRIVALED RECOVERY
AND PURITY
far superior to conventional methods, our technology ensures high cell purity and recovery that consistently outperforms
EFFICIENT, ECONOMICAL,
AND REUSABLE
reusable and cleanable fluidics dramatically reduces the cost, while pre-set cleaning protocols offer unprecedented efficiency
CD138+ Plasma Cell Isolation
The expression of CD138, a marker expressed on the surface of plasma cells, plays a critical role in the identification of plasma cell tumors and multiple myeloma cells.1 While the characteristics of plasma cells can vary depending on the disease stage and biological traits of the patient, studies have proven the prognostic value of specific antigen expression patterns in neoplastic plasma cells.2 Traditionally, the assessment of plasma cells in bone marrow involves a time-consuming and labor-intensive method involving ficoll density gradient separation, which results in the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and analysis.2 This summary focuses on the MARS® platform, developed by Applied Cells, which incorporates their proprietary in-flow immuno-magnetic separation technology to efficiently isolate CD138+ plasma cells directly from unprocessed bone marrow samples. This innovative approach simplifies the isolation process, enabling fast and dependable analysis of CD138 expression in plasma cells.
1. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12(12): 1101-1106.
2. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010 Sep;23(3):433-51.
Directly from Bone Marrow
CD138 expression is important in diagnosing plasma cell tumors and multiple myeloma. This application note highlights the MARS® platform as an innovative tool for efficiently isolating CD138+ plasma cells from peripheral blood mononuclear cell samples. This streamlined approach facilitates rapid and reliable isolation of plasma cells, revolutionizing the research for plasma cell-related disorders.
Download brochure
Case study: CD138 Plasma Cell Enrichment for FISH
Setting New Benchmarks with the MARS® Platform
The MARS® platform offers advanced cell isolation capabilities, surpassing traditional cell isolation methods for FISH assays, consistently meeting the enrichment benchmarks. As we gear up to release the latest detailed case study, discover how MARS® isolated cells can improve FISH tests outcome for the accurate detection of multiple myeloma.
Easy, sequential purification process
The MARS® platform simplifies the cell isolation process through its fast and easy workflow, which improves purity while maintaining high recovery of cells. Our instrument uses an automated one- to three-pass cell enrichment process and involves minimal hands-on time.
Other unique features include matrix-free cell isolation, economical consumables, and sterilizable and reusable fluidics. The obtained samples can also be rapidly re-run through the magnetic channel to maximize efficiency.
Explore other MARS® Platform Applications
Cell Therapy
Explore other MARS® Platform Applications
